Following a successful contribution to the methodological guidance development in EUnetHTA JA (2010-2012), EUnetHTA continued its efforts in JA2 as well.
We are pleased to announce that as of today, 11March 2016, the draft methodological reflection paper “Personalised medicine and co-dependent technologies, with a special focus on study design issues”, produced within WP7 - Subgroup 3, has entered the public consultation phase. This consultation will take place between 11 March and 15 April 2016.
One of the specific objectives of JA2 was to test the capacity of national HTA bodies to produce structured core HTA information (including rapid Relative Effectiveness Assessments (REAs) together and apply it in national context.
“Support for a more centralized European approach to evaluating new health technologies is gaining pace among the national and regional officials who perform this work in the member countries” – declared an opening line of a Health POLITICO-Pro article reporting from the EUnetHTA JA3 kick-off meeting the day after.
During the past 3 years of EUnetHTA’s operations in the framework of the Joint Action 2, an expanded suite of practical approaches and tools for HTA production has been developed and tested through a series of field-testing exercises in EUnetHTA, both in the framework of joint assessments and by individual European HTA organisations in their local HTA processes. The detailed results of these activities will be included in the final technical report to the European Commission (to be delivered in May 2016).